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 Extreme morning chronotypes are often familial and not exceedingly
rare:  The  estimated  prevalence  of  Advanced  Sleep  Phase  (ASP),
Familial Advanced Sleep Phase (FASP), and Advanced Sleep-Wake
Phase Disorder (ASWPD) in a sleep clinic population
Abstract:
Study Objectives: Report the first prevalence estimates of Advanced Sleep
Phase (ASP),  Familial  Advanced Sleep Phase (FASP)  and Advanced Sleep-
Wake Phase Disorder  (ASWPD).  This  can guide clinicians  on the utility  of
screening for extreme chronotypes both for clinical decision making and to
flag prospective participants in the study of the genetics and biology of FASP.
Methods:  Data  on  morning  or  evening  sleep  schedule  preference
(chronotype) were collected from 2,422 new patients presenting to a North
American sleep center over 9.8 years. FASP was determined using a severity
criterion  that  has  previously  identified  dominant  circadian  mutations  in
humans.  All  patients  were  personally  seen  and  evaluated  by  one  of  the
authors (C.R.J.).
Results:  Our  results  demonstrate  an  ASP  prevalence  of  0.33%,  an  FASP
prevalence of  0.21%,  and an ASWPD prevalence of  at  least  0.04%.  Most
cases of young onset ASP were familial. 
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 Conclusions: Among patients presenting to a sleep clinic, conservatively one
out of every 300 patients will have ASP, one out of every 475 will have FASP,
and  one  out  of  every  2,500  will  have ASWPD.  This  supports  obtaining  a
routine circadian history and, for those with extreme chronotypes, obtaining
a circadian family history. This can optimize treatment for evening sleepiness
and  early  morning  awakening  and  lead  to  additional  circadian  gene
discovery. We hope these findings will lead to improved treatment options
for a wide range of sleep and medical disorders in the future. 
Introduction:
Advanced  Sleep  Phase  (ASP)  is  characterized  by  a  stable  and  unusually
phase-advanced circadian sleep-wake rhythm relative to local solar time. We
refer to Familial Advanced Sleep Phase (FASP) when ASP is demonstrated in
multiple biologically related family members.1 Advanced Sleep-Wake Phase
Disorder (ASWPD) is defined as a marked phase advance of the sleep-wake
cycle accompanied by a sleep related complaint. FASP is a subtype of ASP
and  overlaps  with  ASWPD  (Figure  1).   Identifying  these  individuals  in  a
clinical setting appears challenging as they are presumed to be very rare. As
the third edition of the International Classification of Sleep Disorders (ICSD-3)
2
 observes,  “The  existing  literature  suggests  that  clinicians  are  unlikely  to
encounter  patients  with  stringently  defined  ASWPD.”2 The  rarity  of
encountering patients with stringently defined ASWPD is likely a result of the
diagnostic requirement for a chronic or recurrent complaint related to the
patient’s  advanced  sleep-wake  schedule.2 Indeed,  in  patients  with  young
onset ASP, their early morning awakening may not be perceived as a school
or work problem, but rather as an advantage. This may explain why ASP was
thought  to  be  exceedingly  rare  in  the  general  population.3 Many  such
individuals do not seek medical attention for their ASP. Prior to 1999, the
authors  are  aware  of  only  two convincing  case  reports  of  severe,  young
onset ASWPD.4,5 Young onset ASWPD was initially thought to be sporadic, but
one of these case reports alluded to a family history.4 Two other case reports
are difficult to interpret due to conventional morning wake time and difficulty
maintaining sleep in one report6 and late age of onset in another.7 
Another potential obstacle to the clinical identification of patients with ASP,
FASP, and ASWPD is a lack of recommended cut-off scores on widely used
circadian  questionnaires  to  reliably  suggest  unusual  circadian  phase
advance. Two questionnaires commonly used for this purpose are the Munich
Chronotype  Questionnaire  (MCTQ)8 and  the  Horne-Ostberg
Morningness/Eveningness Questionnaire (MEQ).9 Data from Till Roenneberg
and  colleagues’  growing  MCTQ  database8 suggests  that  individual  sleep
schedule on free days, a marker of chronotype, is approximately normally
distributed and varies with latitude, geographical region, and urban or rural
3
 lifestyle.10 Using MSF calculations, chronotype has been shown to delay by
four minutes for each degree of longitude one moves from east to west, even
within the same time zone.10 The average midpoint of  sleep on work-free
days (MSF) corrected for extra catch-up sleep on the weekends (MSFsc) also
has a latitudinal  dependence. In the northerly latitudes of central Europe,
MSFsc is centered on 04:00, whereas MSF distribution in India centers on
03:00.  Therefore,  “intermediate”  chronotypes  in  central  Europe  would  be
“late types” in India.11 Chronotype also has a strong age dependence, with
rapidly increasing phase delay through adolescence that peaks sharply at
age 20 and is  followed by a  gradually  slowing  but  persistent  trend back
toward typical  childhood  chronotype  by  the 8th decade.12 Therefore,  ideal
criteria  for  advanced  sleep  phase  might  incorporate  age,  latitude,  and
longitude.  However,  to  allow  for  routine  clinical  use,  our  experience
identifying and phenotyping FASP kindreds in North America suggests that
individuals and families with a MSF ≤ 01:30; MEQ scores ≥ 71; and onset of
these sleep schedules occurring prior to the age of 30 likely have a familial
form of advanced sleep phase.1,13–19
In 1999, three families containing a total of 29 strikingly phase advanced
individuals were reported by one of the authors (C.R.J.) under the descriptive
term  “Familial  Advanced  Sleep  Phase  Syndrome  (FASPS).”1 We  have
modified  the  term  to  ‘Familial  Advanced  Sleep  Phase  (FASP)’  since
‘syndrome’ may connote a disorder to some while many FASP individuals
have no complaint about their  sleep schedule.  One of these families was
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 used to genetically map and clone the first reported human circadian clock
gene mutation in the hPER2 gene.1,13 The ASP probands in this study were
discovered by C.R.J. because they came to clinical attention with complaints
suggestive of obstructive sleep apnea (OSA). Due to the absence of circadian
complaints, most ASP probands would not meet ICSD-3 diagnostic criteria for
ASWPD.20 For this reason, we refer to individuals and families with the onset
of extreme sleep phase advance by age 30 as Advanced Sleep Phase (ASP)
and Familial Advanced Sleep Phase (FASP), respectively. 
The ASP participants reported here were living urban lifestyles within the
North American state of Utah, comparable with the MCTQ central European
database. The initial MCTQ database (N = 500) suggested that no more than
2%  of  the  general  population  in  Germany  and  Switzerland  were  self-
described  “extreme  early  types,”  with  only  0.8%  having  MSF  ≤  02:00.8
Expansion  of  the  MCTQ  database  (N  ≈  25,000)  found  estimates  of
approximately  2%  of  the  general  population  with  MSF  ≤  02:00  and
approximately 0.67% with MSF ≤ 01:30.12 A more recent expansion of the
MCTQ database of central European responders (N = 92,567) found a mean
MSF (not corrected for workweek sleep deprivation) of 04:58 (±1.56), 2.89%
with MSF ≤ 02:00, and 0.97% with MSF ≤ 01:30 (personal communication, T.
Roenneberg in 2012). Correcting for latitude predicts a mean Utah MSF of
04:37. If our clinic population is representative of the local population, this
would represent the mean MSF for those presenting to the clinic.
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 Comparing the MCTQ with another widely used tool to assess chronotype,
the Horne-Ostberg Morningness/Eveningness Questionnaire (MEQ),9 revealed
reasonable  correlations  between  MEQ  and  MSF  scores  (r  =  -0.73)  in  a
predominantly young adult Dutch population (N = 2,481).21 Pooling MEQ data
from 741 young adults, 484 adults, and 40 elderly participants in London and
the  United  States  yielded  a  weighted  prevalence  estimate  of  extreme
morningness  (i.e.,  MEQ  scores  ≥  71)  of  approximately  0.51%.22–25 Taken
together,  the  MCTQ  and  MEQ  databases  would  predict  a  prevalence  of
individuals with extreme morning chronotypes resembling ASP (i.e., MSF ≤
01:30 and MEQ ≥ 71) to range between 0.50-1.00% in the North American
general population. Whether a similar prevalence range accurately reflects
the prevalence of individuals with young onset ASP and FASP is currently
unknown. 
To address this question, we report here the first estimated prevalence of
young onset ASP, FASP, and ASWPD obtained from a sleep clinic population.
Data on self-report and objective methods used to characterize chronotype
and circadian rhythms in young onset ASP, FASP and ASWPD participants are
provided.  Next,  differences in  self-reported markers  of  circadian rhythms,
excessive  daytime  sleepiness,  and  depressive  affect  in  young  onset  ASP
participants  and  their  conventional  chronotype  family  members  were
examined. Finally, we explore whether apnea hypopnea index (AHI) predicts
MEQ-determined chronotype to gauge whether using a population presenting
with symptoms of OSA has potential for generalizability of the results.
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 Methods:
Research approval for this study was obtained from the University of Utah
Institutional Review Board.
Participants
As in many general sleep disorder clinics, most participants presented for
signs and symptoms concerning for OSA. This is not surprising,  given the
high prevalence of OSA in men and women and the availability of clinical
treatment options.2 Name, hospital medical record number, date of first visit,
new versus return physician evaluation code, and diagnosis code numbers
for all patients seen by C.R.J. from January 1994 through October 2003 were
imported from our hospital’s scheduling and billing computer record system
into  an  Excel  spreadsheet.  The  spreadsheet  was  then  edited  to  delete
patient encounters other than the initial patient visit. Computer data entry
from January  1994 to  August  1995 did  not  use  sufficiently  specific  sleep
disorder  diagnosis  codes  or  discriminate  nighttime  sleep  laboratory
procedures performed by technologists  from daytime clinic visits with the
physician. However, of the 637 encounters from this period, 571 complete
paper charts were available for review and the appropriate diagnosis and
procedure codes were manually entered into the edited spreadsheet. The
total  number  of  patients  seen  was  2,422,  of  whom  1,748  (72.2%)  had
suspected or proven OSA. 
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 Screening for Advanced Sleep Phase (ASP)
Careful  screening  for  ASP  began  following  identification  of  the  first  FASP
proband seen by C.R.J.  in November of 1992. This 72-year-old female was
first described in 1999.1 Habitual workday and free day sleep schedules were
routinely  discussed with  patients  during their  initial  clinic  visit,  given the
relevance of sleep timing to all sleep disorders. Patients describing MSF ≤
01:30 with onset of this sleep schedule prior to age 30 were informed of our
research following their clinic visit. Willing participants signed a consent form
approved by the University of Utah Institutional Review Board. Initial contact
and enrollment of patient’s family members was accomplished by telephone,
email, or U.S. Postal Service. 
Expanded Phenotyping of Patients Screening Positive for ASP and Their
Family Members
Enrolled  participants  were  asked  to  complete  six  questionnaires:  1)
Participant Information Form detailing demographic information and family
medical history;  2) Epworth Sleepiness Scale (ESS)26;  3)  A “General Sleep
Questionnaire” (GSQ) we designed to assess habitual workday and free day
sleep  schedules,  sleep  disorders,  medical  history,  and  psychosocial
influences on sleep (Supplemental Figure 1); 4) A visual-analog “Wake and
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 Sleep Questionnaire” developed to assess latencies from lights out to initial
sleep onset and from final sleep offset to getting out of bed (Supplemental
Figure  2);  5)  Morningness/Eveningness  Questionnaire9;  and  6)  Beck
Depression Inventory II (BDI-II).27 Participants also completed a 45-60 minute
structured  telephone  interview  conducted  by  C.R.J.  or  a  trained  research
coordinator.  Interview  questions  included  habitual  workday  and  free  day
sleep schedules, alarm use, daytime napping, daily rhythms of mood and
alertness, effects of seasonal and time-zone changes on sleep, confounding
influences on sleep (e.g.,  caffeine,  alcohol),  age-related changes  in  sleep
schedule,  and  age-related  history  of  chronotype  from  childhood  to  the
present (Supplemental Figure 3). This detailed screening included evaluation
for  alternative  causes  of  early  morning  awakening  such  as  depression,
daytime obligations, insomnia, and OSA.
When  possible,  questionnaires  and  structured  interview  results  were
compared  with  in-laboratory  polysomnography  (PSG),  home  sleep-stage
recordings,  and 10-day ambulatory  wrist  actigraphy with  coincident  sleep
logs,  and one evening of  salivary dim light  melatonin onset (DLMO).  The
phase angle between melatonin onset and the sleep-wake cycle has been
correlated with endogenous circadian period28 and the DLMO itself estimates
the magnitude of circadian rhythm advance or delay. PSG was recorded and
scored according to standard procedures.29,30 Home sleep-stage recordings
were  performed  using  the  Zeo  automated  wireless  system  (Zeo,  Inc.,
Newton,  MA)  that  has  shown  reliability  with  in-lab  PSG31 and  outpatient
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 actigraphy and sleep logs.32 Actigraphy was performed using the MicroMini-
Motionlogger  (Ambulatory  Monitoring,  Inc.,  Ardsley,  NY)  and  Actiwatch-L
(Respironics, Murrysville, PA) actigraphs. Actigraphy data were downloaded
using  Action-W  2.4.17  and  Actiware-Sleep  3.4  software  and  scored
automatically  using  the  Cole-Kripke  sleep  algorithm.  Saliva  samples  to
determine  DLMO  were  collected  every  30  minutes  for  5-6  hours  before
habitual  bedtime  on  non-workdays  by  participants  in  their  homes  using
“Salivette” saliva collection tubes (Sarstedt, Inc., Newton, NC). SolidPhase,
Inc. (Portland, ME) analyzed saliva melatonin content using the BUHLMANN
Direct Saliva Melatonin Radio Immunoassay (ALPCO Diagnostics, Salem, NH).
Participants were instructed to remain in ≤ 30 lux of dim lighting throughout
their  saliva  collection  protocol.  Lux  values  were  obtained  using  the
Sinometer LX1010B Mini Digital Lux Meter (ShenZhen, China) and recorded
on a saliva collection log at the time of each saliva sample. 
ASP criteria included the following: 1) the ability to fall asleep before 20:30
and to wake before 05:30 throughout the year in the absence of professional
or psychosocial demands or environmental influences (e.g.,  early morning
work start-time, self-imposed morning bright light); 2) the presence of only
one major sleep period each day; 3) onset of this stable sleep-wake schedule
before the age of 30;  4) the sleep pattern is  not maintained by morning
stimulants or  evening sedative use;  5)  the sleep pattern did not  develop
within 3 months of a traumatic brain injury; and 6) the sleep pattern is not
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 due  to  another  medical,  neurological,  or  mental  disorder  (e.g.,  chronic
insomnia disorder, major depressive disorder). 
Apnea Hypopnea Index Predicting MEQ-Determined Chronotype
To  gauge  whether  an  OSA  population  is  skewed  toward  morningness  or
eveningness, we assessed whether AHI selects for MEQ using the Wisconsin
Sleep  Cohort.  Repeated  measures linear  regression  analysis  (Proc  Mixed,
SAS) was  performed  on  MEQ  and  the  log  of  the apnea  hypopnea  index
(AHI) scores  from 3,188  studies  on 1,324  participants  from the Wisconsin
Sleep  Cohort. The  Wisconsin  Sleep  Cohort’s  methods  for  collection  and
interpretation of PSG recordings and AHI scores have been described.33
Results:
Estimated North American Prevalence of Early Onset ASP and FASP
Eight patients with ASP (three females) were identified and enrolled from
January  1994  through  October  2003  (9.8  consecutive  years).  Seven  ASP
subjects presented with excessive daytime sleepiness (EDS) as their primary
complaint.  The eighth ASP subject presented with a previous diagnosis of
OSA, complaining of nasal continuous positive airway pressure (CPAP) mask
discomfort. Diagnostic PSG demonstrated OSA in all five male ASP subjects.
The  first  female  ASP  proband  had  suspected  upper  airway  resistance
syndrome  and  declined  PSG  and  multiple  sleep  latency  testing  (MSLT),
12
 anticipating a change in her condition after completion of her pregnancy.
Subsequently, she had upper airway surgery with self-reported resolution of
her hypersomnia. The second female ASP proband presented with worsening
EDS  secondary  to  a  previous  diagnosis  of  narcolepsy  without  cataplexy.
Diagnostic PSG demonstrated obstructive hypopneas of mild degree (AHI =
11) plus respiratory effort related arousals of approximately five per hour in
supine and lateral positions. The third female proband was diagnosed with
insufficient  sleep  associated  with  advanced  sleep  phase  syndrome  and
possible idiopathic hypersomnia without long sleep time following PSG and
MSLT recordings. 
No ASP probands presented with chief complaint of their advanced schedule,
and it was thought to contribute to the ultimate diagnosis in one of eight
patients.  Two  probands  had  ASP  onset  before  the  age  of  12  and  the
remaining six probands had ASP onset before the age of 22. All eight ASP
probands reported at least one first-degree relative with a similarly advanced
sleep-wake schedule, suggesting FASP. At least one relative with ASP from
each proband was willing to be interviewed for research purposes. Family
member enrollment and circadian phenotyping revealed 15 ASP participants
in  five  families,  confirming  FASP  in  five  kindreds  consistent  with  an
autosomal dominant mode of transmission (Figure 2). Two ASP relatives had
age of onset by age 40, with the remaining ASP relatives having onset prior
to the age of 22.
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 Of the 2,422 patients that were seen from January 1994 through October
2003, eight ASP probands and five FASP kindreds were identified who met
our  ASP criteria.  One ASP proband had a  sleep  complaint  related to  her
advanced sleep schedule. Therefore, the estimated prevalence of early onset
ASP,  FASP  and  ASWPD  among  patients  pursuing  evaluation  at  a  North
American academic medical center is 0.33% (8/2,422), 0.21% (5/2,422), and
0.04% (1/2422) respectively (Figure 3). We consider these estimates to be
conservative,  as  four  subjects  describing  FASP  declined  research
participation  and  were  not  included  in  the  above  results.  If  these  4
individuals  do,  in  fact,  have  ASP,  the  ASP  prevalence  estimate  is  0.50%
(12/2,422). Assuming the 4 to have FASP, an upper estimate of FASP from
the dataset would be 0.37% (9/2,422). Further, more mild sleep patterns that
did not meet our strict criteria were seen in family members of the three ASP
individuals who were not categorized as FASP. Four additional individuals and
eight of their relatives were also initially enrolled in our study but ultimately
were not included in this data due to not meeting the strict criteria. 
We also considered the prevalence estimate for ASP and FASP among the
population  pursuing  evaluation  for  OSA  whose  ASP  was  not  thought  to
directly contribute to the diagnosis. Of the 1,748 patients with suspected or
proven OSA that were seen from January 1994 through October 2003, seven
patients met criteria  for  ASP and four for  FASP.  Therefore,  the estimated
prevalence of early onset ASP and FASP among patients pursuing evaluation
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 at a North American academic medical center for symptoms of OSA is 0.40%
(7/1,748) and 0.23% (4/1,748), respectively.
Chronotype and Circadian Rhythm Markers of Young Onset ASP and
FASP Participants
MEQ scores, MSF times, and saliva DLMO for the ASP probands and their ASP
relatives are included in Table 1. 
Fourteen non-advanced and non-delayed (i.e.,  “conventional”)  chronotype
family members were also identified and characterized in our ASP and FASP
kindreds. Comparison between self-reported markers of circadian rhythms,
excessive daytime sleepiness, and depressive affect in ASP participants and
their  conventional  chronotype  family  members  are  included  in  Table  2.
Comparison  of  MSF  and  MEQ in  the  ASP  cohort  versus  the  conventional
sleeping family members is demonstrated in supplemental Figure 4.
 
Apnea  Hypopnea  Index  Severity  Does  Not  Predict  MEQ-Determined
Chronotype
The majority  of  the ASP and FASP probands in this  investigation pursued
evaluation at an academic medical center for symptoms of potential OSA. To
assess if OSA selects for chronotype, data was obtained on MEQ and apnea
hypopnea index (AHI) scores from 3,188 studies on 1,324 participants from
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 the Wisconsin Sleep Cohort.33 Repeated Measures Linear regression analysis
revealed  no  significant  predictive  relationship  between  MEQ-determined
early  morning  or  late  night  sleep  schedule  preference  and  AHI  severity
(Figure 4).
Discussion:
In this study, we provide the first prevalence estimates of ASP, FASP, and
ASWPD based on a sleep clinic population. All patients were personally seen
and evaluated by one of our authors (C.R.J.). Of the eight young onset ASP
probands, five FASP families were identified who met our strict ASP criteria.
Estimates show an ASP prevalence of 0.33% (8/2,422), FASP prevalence of
0.21% (5/2,422), and ASWPD prevalence of 0.04% (1/2422) (Figure 3). Of the
2,422  total  patients,  1,748  presented  for  OSA.  Therefore,  the  estimated
prevalence  in  an  OSA  population  is  0.40%  (7/1,748)  for  ASP  and  0.23%
(4/1,748) for FASP. As the eighth proband did not have OSA and instead had
a  complaint  related  to  FASP,  she  meets  criteria  for  ASWPD  and  is  not
included in the estimate from an OSA population.
Data characterizing chronotype and circadian rhythms using subjective and
objective methods for the 8 young onset ASP probands and their ASP family
members in this study are given in Table 1.  Clock times are reported in
participants’  local  time zone and not  solar  time.  MCTQ data from 21,600
German participants  strongly  suggests  that  the  human circadian  clock  is
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 predominantly  entrained  by  solar  time  rather  than  local  legal  (“social”)
time.10 Therefore, we consider our phenotyping to be conservative, as four
ASP probands and one ASP relative performed recordings during Daylight
Saving Time, effectively delaying these clock times by one hour in reference
to solar  time.  Three ASP probands (32966,  101344,  and 51146)  reported
routinely  delaying  their  evening  sleep  onset  to  avoid  early  morning
awakening,  making  their  advanced  MSF  times  all  the  more  impressive.
Proband 101263 denied delaying evening sleep onset, and we were unable
to  collect  this  information  from  probands  25823,  28414,  100381,  and
101311. Salivary DLMOs collected on 170 North American adult participants
(85 females, average MEQ = 52.11 ± 9.10) revealed a mean DLMO of 20:50
(±1:12).37 Using the same method of DLMO calculation, ASP proband 101311
is  within  the  earliest  0.21%  of  this  normative  database.  Similarly,  ASP
proband 28414 and ASP family member 101382 are within the earliest 0.50%
and 20.5% of this normative database, respectively. As 101382 performed
her DLMO during Daylight Saving Time, she would be predicted to be within
the earliest  4.7% of  this  normative  database using solar  (i.e.,  non-social)
time. Due to financial constraints, sleep logs, actigraphy, Zeo, DLMO, and
PSG  data  were  collected  on  fewer  conventional  chronotypes  than  ASP
participants, limiting statistical comparisons on these measures. 
Significant differences in MSF clock times and MEQ scores and between ASP
participants  and  their  conventional  chronotype  family  members  were
expected given our ASP classification criteria (Table 2, Supplemental Figure
17
 4). The tendency towards rigid sleep schedules on workdays (MSW) and non-
workdays  (MSF)  in  “extreme early  types”  have been  reported  in  a  large
North American FASP kindred1 and a European study using the MCTQ.8 Our
data confirm this tendency. Young onset ASP participants sleep an average
of 5-10 minutes later on weekends compared to an average of 30-38 minutes
for their conventional chronotype family members (Table 2). Latency of final
sleep  offset  (Speed WU)  was  determined  using  a  visual-analog  scale  we
developed that ranges from 0-100: “On awakening most mornings, how long
does it take you to become fully alert and active?” (0 = several hours; 100 =
seconds; Supplemental Figure 2). Our findings suggest that ASP individuals
feel alert more quickly in the morning, i.e. have less sleep inertia, compared
to their conventional chronotype family members (Table 2). The tendency for
morning  types  to  be  more  subjectively  alert  upon  awakening  may  be
explained,  in  part,  by  core  body temperature rhythms.  Previous  research
suggests that morning types sleep at a later portion of their temperature
rhythm compared to conventional and evening chronotypes.24 
No  significant  differences  were  observed  in  Beck  Depression  Inventory
scores between ASP participants and their family members with conventional
chronotypes  (Table  2).  This  supports  that  early  morning  awakenings
observed  in  ASP  and  FASP  probands  are  not  the  result  of  comorbid
depression.  No  significant  differences  were  observed  between  ASP
participants  and  their  conventional  chronotype  family  members  in  self-
reported daytime sleepiness (Table 2). Elevated ESS scores may be expected
18
 for the eight ASP probands who each presented with clinical symptoms of
EDS related to OSA (n = 7) or idiopathic hypersomnia (n = 1). However, ESS
scores from these eight ASP probands were combined with ESS scores from 7
FASP family  members  (total  n  = 15),  which  may account  for  these non-
significant  results.  Sleep  quality  and  quantity  are  typically  reported  as
normal for age when ASWPD patients without comorbidities allow themselves
to fall asleep and awaken without regard to social constraints.2 
Our method of screening for FASP began with habitual sleep time and thus
does  not  account  for  individuals  who  may  be  advanced  but  can  easily
overcome  their  circadian  clock  and  sleep  at  a  more  conventional  time.
Additionally, our criteria rely on mid-sleep time on free days and responses
to  the  MEQ,  which  may  have  excluded  some  individuals  who  appear
advanced by other measures. While this may lead to an underestimate of
ASP, our rigorous screening method has proven effective in identifying FASP.
These strict criteria avoid false positives and increases the yield for genetic
screening in families with a dominant pattern of inheritance. This method
has led to successful identification of multiple clock genes that co-segregate
in the family and are then recapitulated in mouse models.1,13,15,17,18 Therefore,
this screening method can translate simple questions about sleep timing on
an  entry  sleep  clinic  questionnaire  into  identification  of  families  with  an
autosomal dominant sleep trait and lead to identification of genes controlling
our circadian clock. 
19
 Our ASWPD prevalence estimate of  0.04% includes only  those individuals
presenting with  ASP prior  to  age 30.  This  estimate  does  not  account  for
individuals with ASP of aging, whose schedule advance with aging prompts
complaint.  Therefore,  the present  estimate likely  underestimates the true
prevalence  of  ASWPD,  even  within  a  sleep  clinic  population.  Figure  1
illustrates the relationship between ASP, FASP, ASWPD, and ASP of aging.
FASP represents the majority of young onset ASP, and a small portion of this
group  will  complain  of  their  advanced  phase,  thus  falling  into  ASWPD.
However,  some  with  ASWPD may  have  ASP  only  due  to  aging  or  other
unidentified causes. While it is known that chronotype advances with age,
the  formal  definition  and  prevalence  of  ASP  of  aging  is  not  defined.12
Therefore  the  relative  size  of  the  circles  in  figure  1  does not  reflect  the
relative prevalence of  ASP vs.  ASP of  aging,  as the prevalence of  ASP of
aging is not known. 
The young onset ASP and FASP prevalence estimates reported here were
based on a clinical population presenting to an academic medical center. We
have also calculated the prevalence from the population presenting only for
OSA, resulting in an ASP prevalence of 0.40% (7/1,748) and FASP prevalence
of 0.23% (4/1,748).  This limited sample was used because we can assess
whether this sample selects for chronotype and thus can consider whether
the estimate may have a potential for generalizability. We conducted a linear
regression analysis of MEQ and AHI scores from 1,324 participants using the
Wisconsin Sleep Cohort database (Figure 4). Results of this analysis found no
20
 significant  predictive  relationship  between these variables,  indicating that
using a sleep clinic  population  presenting for  symptoms of OSA does not
appear to bias the chronotype of the sample. Whether our ASP and FASP
prevalence estimates can be further generalized to the population merits
additional  investigation.  Additionally,  as  our  team  published  research  on
FASP beginning in 1999; it is possible this altered the patient group seeking
care in the clinic,  making this clinic estimate less representative of  other
sleep clinics. This is not a population-based sample. 
We aim to raise awareness about ASP and FASP with the hope this prompts
routine screening, enhancing clinical  care for those affected. It  is  notable
that  many  with  ASP  and  FASP  are  not  troubled  by  this  sleep  pattern.
Increased  awareness  will  improve  screening  for  these  phenotypes  and
enrollment in related research. Taken together, our findings suggest that ASP
and FASP subjects routinely present to sleep centers with primary complaints
that do not appear directly related to sleep-wake schedule advance. Our ASP
and FASP prevalence estimates are higher than one would predict based on
the prevailing understanding of ASP from ASWPD. Our data supports  that
ASWPD is very rare at one out of every 2,500. Milder versions or those who
develop ASP of aging are not accounted for in the dataset. 
In our clinical experience, a six-bed sleep clinic running five nights per week
may see 1,500 patients and perform 450 new diagnostic PSGs annually. Our
FASP  prevalence  estimate  of  0.21%  would  predict  approximately  one
incidental FASP PSG recording per six-bed sleep center per year. The 2016-
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 2017 American Academy of Sleep Medicine (AASM) Membership Directory
(www.aasmnet.org)  lists  1,512  AASM-accredited  sleep  centers  currently
operating  within  the  United  States.  Therefore,  approximately  1,000
diagnostic PSG recordings may be performed on potential OSA patients who
also  have  FASP  in  the  United  States  annually.  This  number  is  likely
conservative,  as  1,615,135 PSG recordings  were  estimated to  have been
performed in the United States in the year 2001.34 Assuming only 50% of
these recordings were performed for new patient OSA evaluations, our FASP
prevalence  in  an  OSA  population  estimate  of  0.23%  predicts  1,857  PSG
recordings  were  performed  on  potential  OSA  patients  with  FASP  in  2001
alone.  To  our  knowledge,  only  11  FASP  families  have  been  reported  to
date,1,15–18,35,36 suggesting that there is  potential  to identify  far more FASP
individuals during routine clinic evaluation.
Individuals  with ASP often complain of  a longstanding pattern of  evening
sleepiness  and  early  morning  awakening  with  trouble  returning  to  sleep.
They may have shorter sleep hours if attempting to stay up for social, work,
or family obligations without the ability to awaken later. There is a growing
body of literature linking fewer hours of sleep to multiple negative health
outcomes  including  increased  mortality,  diabetes  mellitus,  hypertension,
cardiovascular  disease,  and  obesity.38 It  is  essential  for  clinicians  to
appreciate the circadian explanation for shorter sleep hours for this patient
population to provide appropriate counseling and treatment options.
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 Therefore, we recommend routine screening for circadian phenotypes in all
sleep clinics with two questions: 
1)  On  a  long  weekend  or  vacation  with  few  or  no  responsibilities  or
obligations, when would you go to bed?
2)  On  a  long  weekend  or  vacation  with  few  or  no  responsibilities  or
obligations, when is your final awakening for the night? 
These  simple  questions  included  in  new  patient  packets  can  allow  the
clinician to screen for both ASP and DSP, with follow up questions if atypical
timing  is  noted.  Asking  about  long  weekend  and  vacation  rhythms  is
important to remove the extrinsic demands of school, work, and family and
rebound sleep during weekends. 
Recognizing that extreme sleep-wake schedule advance is not exceedingly
rare may assist clinicians in separating the early morning awakenings of ASP
from the  early  morning  awakenings  of  insomnia,  nocturia,  environmental
sleep disruptions, and major depressive disorder. Identifying FASP subjects
will require clinicians to routinely ask about habitual workday and free day
sleep-wake schedules and explore familial patterns of ASP if extreme sleep-
wake schedule advances are described.  Our findings further suggest  that
ASP individuals with onset prior to age 30 should be considered likely FASP
probands. 
Importantly, the clinical identification of young onset FASP individuals and
their family members  has facilitated the discovery of autosomal dominant
circadian  clock  gene  mutations  in  hPer2,13,14 CKIδ,15,16 PERIOD3,17 CRY2,18
23
 TIM,39 and  DEC2.19 FASP  clock  gene  mutations  have  been  found  to  co-
segregate with familial migraine (casein kinase 1δ)15  and depressive affect
(PER3),17 and regulatory roles for core clock genes in tumor suppression,40
sugar metabolism,41 behavioral activation,19 and the age of onset of bipolar
disorder42 have  been  reported.  Therefore,  functional  characterization  of
newly  discovered  clock  gene mutations  may lead to  improved  treatment
options for a wide range of sleep and medical disorders in the future. Our
findings  provide  an  indication  and  mechanism  for  clinicians  to  routinely
screen for ASP and FASP subjects.
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Figures 
Figure  1:  Venn  diagram of  relationship  between  advanced  sleep  phase
(ASP),  familial  advanced sleep phase (FASP),  advanced sleep-wake phase
disorder (ASWPD) and ASP of aging
Figure 2: FASP Pedigrees. Circles: females. Squares: males. Diagonal line
through symbols: deceased. Numbers underneath symbols: DNA identifier.
Arrows: probands.
Figure 3: Flow chart of patient enrollment and prevalence estimates.
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 Figure 4:  Apnea Hypopnea Index (AHI) Severity  Does Not Predict
Morningness-Eveningness  Questionnaire  (MEQ)-Determined
Chronotype. Note:  N  = 3,188. Females: 1491 (mean age = 57.7). Males:
1697 (mean age: 59.4). Mean MEQ scores = 62.08 ± 9.71. Mean AHI scores
= 14.08 ± 17.78. Trend line reveals no significant relationship between AHI
and MEQ (β = 0.08, SE β = 0.13, p = 0.52, R2 = 1.0 e-5). 
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